TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29813149
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral vitamin D3 supplementation of 400 IU
Study: 27814853
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy protocol with emphasis on techniques of joint mobilization and soft-tissue management
Study: 24469611
Drug: 3‐session social
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐session social learning and cognitive-behavioral treatment (N=100)
Study: 22484579
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg through a nasogastric tube 30 minutes before induction of anesthesia)
Study: 19695194
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 mL normal saline)
Study: 8058235
Drug: Alprazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25 mg three times a day)
Study: 2564011
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA, 600 mg/day)
Study: 29596951
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR (60-120 mg once daily)
Study: 22092732
Drug: 0.1% 8-methoxypsoralen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% 8-methoxypsoralen (8MOP) cream before NBUVB phototherapy
Study: 16978159
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg/kg bolus followed by 0.4 microg/kg/h infusion)
Study: 23607215
Drug: 800 ml/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 ml/day of remaxol
Study: 23607215
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution and 10% glucose at 1:1 ratio
Study: 12417161
Drug: Moist Exposed
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist Exposed Burn Ointment (MEBO) application
Study: 12621572
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic ointment application
Study: 12621572
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical therapy
Study: 7697233
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (600 mg/d)
Study: 7697233
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (15 mg/kg/d of trimethoprim plus 75 mg/kg/d of sulfamethoxazole)
Study: 28117875
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 8% (24-hour pretreatment)
Study: 28117875
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 8% (1-hour pretreatment)
Study: 26003433
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (rivaroxaban and ticagrelor)
Study: 26003433
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (warfarin, clopidogrel, and aspirin)
Study: 23232491
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and carboplatin with cediranib (30 mg daily)
Study: 16704649
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg kg(‐1) induction at weeks 0, 2 and 6 followed by maintenance every 8 weeks
Study: 16704649
Drug: Infliximab maintenance
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab maintenance therapy
Study: 9129564
Drug: Oral methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylnaltrexone (19.2 mg/kg)
Study: 9129564
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.05 mg/kg)
Study: 9129564
Drug: Oral methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylnaltrexone (6.4 mg/kg)
Study: 8399073
Drug: IL‐2, 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2, 9 mIU/m2/day by continuous intravenous infusion on days 1‐5, 8‐12, and 15‐19 with doxorubicin, 25 mg/m2 on day 14.
Study: 8399073
Drug: IL‐2, 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2, 13.5 mIU/m2/day by continuous intravenous infusion on days 1‐5, 8‐12, and 15‐19 with doxorubicin, 25 mg/m2 on day 14.
Study: 8399073
Drug: IL‐2, 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2, 18 mIU/m2/day by continuous intravenous infusion on days 1‐5 and 8‐12 with doxorubicin, 50 mg/m2 on day 7.
Study: 8399073
Drug: IL‐2, 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2, 18 mIU/m2/day by continuous intravenous infusion on days 1‐5 and 8‐12 with doxorubicin, 25 mg/m2 on day 7.
Study: 2868549
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (Persantine)
Study: 25200049
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus placebo
Study: 29561248
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of PPSV23 and QIV
Study: 29561248
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of PPSV23 and QIV (control)
Study: 15953576
Drug: L-arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (1 g/min)
Study: 10397411
Drug: CO2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 inhalation for 20 minutes in panicking subjects with panic disorder
Study: 10397411
Drug: CO2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 inhalation for 20 minutes in normal comparison subjects
Study: 10397411
Drug: CO2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 inhalation for 20 minutes in non-panicking panic disorder patients
Study: 1801561
Drug: Gamma-globulin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-globulin treatment
Study: 6141186
Drug: Flutroline hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutroline hydrochloride (1, 5, 10, 20, and 100 mg daily)
Study: 27310568
Drug: Affect-guided physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affect-guided physical activity prescription
Study: 27310568
Drug: Heart rate-guided
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate-guided prescription
Study: 17974109
Drug: Chemically modified
Normalized name: Chemically modified recombinant sulfamidase
DrugBank: SOBI-003 (DB15451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemically modified SLA surface implants
Study: 17974109
Drug: Standard SLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SLA surface implants
Study: 15472817
Drug: Micafungin 50
Normalized name: micafungin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 50 mg per day
Study: 15472817
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg per day
Study: 15472817
Drug: Micafungin 150
Normalized name: micafungin 150 MG in 150 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 150 mg per day
Study: 15472817
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg per day
Study: 11743140
Drug: All diets
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All diets during the oral glucose tolerance test (GTT)
Study: 11743140
Drug: All diets
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All diets (24-hr glucose and insulin profiles)
Study: 7843202
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (n = 5)
Study: 2979247
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nocte
Study: 2979247
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg b.d.
Study: 2979247
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg b.d.
Study: 26686968
Drug: Amniotic membrane
Normalized name: Amniotic Membrane Human Ophthalmic Sheet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic membrane transplantation (AMT) with medical therapy (MT)
Study: 26686968
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (MT) alone
Study: 25291577
Drug: H7N9 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 vaccine (3.75 µg) with MF59 adjuvant
Study: 25291577
Drug: H7N9 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 vaccine (15 µg) with MF59 adjuvant
Study: 25291577
Drug: H7N9 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 vaccine (unadjuvanted)
Study: 25291577
Drug: H7N9 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 vaccine (various doses)
Study: 25291577
Drug: H7N9 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 vaccine (with adjuvant)
Study: 20881504
Drug: NaHCO3 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.3 g·kg‐1)
Study: 18564953
Drug: Naturopathic Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic Medicine (NM)
Study: 9006584
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement therapy
Study: 8612442
Drug: Alcohol use
Normalized name: Vorvida Problematic Alcohol Use Support Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol use > 30 g/day
Study: 8612442
Drug: Alcohol use
Normalized name: Vorvida Problematic Alcohol Use Support Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol use ≤ 30 g/day
Study: 8769617
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg daily)
Study: 7033353
Drug: Sucralfate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (4 grams in four divided doses each day)
Study: 7033353
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg three times a day, 400 mg at night)
Study: 28337719
Drug: Adherence intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adherence intervention to nebulised and inhaled antibiotics
Study: 12211217
Drug: Orlistat with
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat with selected concomitant medications (amitriptyline, atorvastatin, cyclosporine, losartan, metformin, phentermine, and sibutramine)
Study: 12211217
Drug: Selective concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective concomitant medications and orlistat
Study: 12211217
Drug: Selective concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective concomitant medications alone
Study: 10573044
Drug: Leflunomide treatment
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide treatment (20 mg/d)
Study: 10573044
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment (7.5-15 mg/wk)
Study: 8918487
Drug: Chemotherapy (carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (carboplatin, etoposide, and bleomycin)
Study: 8918487
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy (carboplatin, etoposide, bleomycin, and cyclophosphamide)
Study: 8918487
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (without irradiation)
Study: 8918487
Drug: Successful salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful salvage therapy
Study: 8918487
Drug: Toxicity associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicity associated with study chemotherapy
Study: 31691370
Drug: Dexamethasone implant
Normalized name: dexamethasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone implant
Study: 24174657
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone (TH) treatment
Study: 20602123
Drug: Customised orthotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customised orthotic insoles (treatment group, n = 73)
Study: 17372175
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H)
Study: 7853170
Drug: Abecarnil (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil (10, 20, 40 mg)
Study: 7853170
Drug: Alprazolam (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.0, 2.0, 4.0 mg)
Study: 7853170
Drug: Alprazolam (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (high dose)
Study: 7853170
Drug: Abecarnil (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil (high dose)
Study: 7080851
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol decanoate injections (20 times and thereafter 15 times the optimal oral haloperidol dose)
Study: 7080851
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol decanoate injections
Study: 24701585
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol (Group T)
Study: 22240407
Drug: Azithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (30 mg/kg oral dose)
Study: 22240407
Drug: Benzathine benzylpenicillin
Normalized name: Benzathine benzylpenicillin
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Benzathine benzylpenicillin (50,000 units/kg intramuscular injection)
Study: 17959952
Drug: Esmolol (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (continuous infusion of 5-15 microg x kg(‐1) x min(‐1))
Study: 17959952
Drug: Control (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intermittent doses of fentanyl)
Study: 17959952
Drug: Remifentanil (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (continuous infusion of 0.1-0.5 microg x kg(‐1) x min(‐1))
Study: 17959952
Drug: Esmolol (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (continuous infusion)
Study: 10338454
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment
Study: 3551432
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment
Study: 14727969
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy combined with early use of tirofiban and standard medical therapy
Study: 9521971
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (0.5 g topically 1 hour before circumcision)
Study: 7619356
Drug: 7.5 mg/day
Normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/day moexipril
Study: 7619356
Drug: 180 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg/day verapamil-SR
Study: 22858124
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day lutein
Study: 22858124
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day lutein
Study: 22858124
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day lutein plus 10 mg/day zeaxanthin
Study: 8762730
Drug: dexfenfluramine (d-FF)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexfenfluramine (d-FF) 15 mg twice daily for 6 days
Study: 30323234
Drug: New administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: New administration route (NEW.AR) of alprostadil cream
Study: 30323234
Drug: Standard administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard administration route (ST.AR) of alprostadil cream
Study: 29467437
Drug: Accelerated rTMS
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated rTMS (n = 58): 63,000 high frequency rTMS pulses delivered as 3 treatments per day over 3 days in week 1, 3 treatments over 2 days in week 2 and 3 treatments on a single day in week 3
Study: 27414655
Drug: CYD‐TDV (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD‐TDV (recombinant live attenuated tetravalent dengue vaccine)
Study: 22846190
Drug: Vacuum interferential
Normalized name: thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vacuum interferential current (IFC) therapy, 12 sessions over 4 weeks.
Study: 22846190
Drug: Placebo therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy, 12 sessions over 4 weeks.
Study: 20171127
Drug: Benzodiazepine hypnotics
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine hypnotics and Z-drugs (e.g., zolpidem, zopiclone, zaleplon)
Study: 20171127
Drug: Benzodiazepine hypnotics
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine hypnotics and Z-drugs
Study: 20171127
Drug: Benzodiazepine hypnotics
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine hypnotics and Z-drugs with alcohol co-administration
Study: 20171127
Drug: Repeated daily
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated daily use of hypnotic drugs
Study: 19112511
Drug: Oral Polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Polio Vaccine (OPV) at birth
Study: 15853109
Drug: Optibond dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optibond dual cure (OPTB) with light-curing (LC) and combination of light and chemical curing (LCC)
Study: 15853109
Drug: Light-curing (LC)
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-curing (LC) and combination of light and chemical curing (LCC)
Study: 9060198
Drug: No-additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-additional treatment control group
Study: 8457152
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (20-Gy) + postoperative low-dose external-beam radiotherapy (35- to 40-Gy)
Study: 8457152
Drug: Postoperative high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative high-dose external-beam radiotherapy (50- to 55-Gy) alone (Control)
Study: 3636335
Drug: Timentin in
Normalized name: Timentin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timentin in combination with amikacin
Study: 26073872
Drug: Dexmecamylamine 2
Normalized name: Dexmecamylamine
DrugBank: Dexmecamylamine (DB11807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmecamylamine 2 mg
Study: 26073872
Drug: Dexmecamylamine 1
Normalized name: Dexmecamylamine
DrugBank: Dexmecamylamine (DB11807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmecamylamine 1 mg
Study: 18326731
Drug: Indomethacin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.4 mg/kg bolus followed by 0.4 mg/kg/h continuous infusion for 120 minutes)
Study: 16782912
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg by mouth twice daily)
Study: 12932066
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anaesthesia with hyperbaric bupivacaine 7.5 mg 0.5% (Group Spinal)
Study: 11119192
Drug: Propofol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (12 mg.kg(‐1).h(‐1)) and alfentanil (0.04 mg.kg(‐1).h(‐1))
Study: 11119192
Drug: Ketamine racemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine racemate (10-12 mg.kg(‐1).h(‐1)) and midazolam (0.3-0.6 mg.kg(‐1).h(‐1))
Study: 8241695
Drug: Ubiquinone (coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinone (coenzyme Q10), 100 mg/day for 7 months
Study: 29212528
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational and physical therapy
Study: 19880138
Drug: Hydroxyurea (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (not specified dosage or duration)
Study: 17696962
Drug: High-dose esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose esomeprazole (40 mg b.d.)
Study: 17696962
Drug: Low-dose esomeprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose esomeprazole (40 mg o.d.)
Study: 11930093
Drug: Intensive Medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Medical Therapy (IMT)
Study: 2565728
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg WY-45,727